Bausch Health Companies Inc. Q4 2025 Earnings Call Summary

Core Insights - The company experienced improved performance in the Diversified segment due to better net pricing in Q4 [1] - Strategic acquisitions, such as Shibo in China and DURECT's larsucosterol platform, indicate a shift towards proactive business development for long-term growth [1] - Full-year adjusted EBITDA growth of 10% was attributed to portfolio optimization and increased operating leverage without major acquisitions [1] International Segment Performance - Growth in the International segment was supported by strong market positions in dermatology and gastroenterology across EMEA, Canada, and Latin America [2] - Solta Medical achieved robust 18% full-year growth, driven by strong demand in Asia Pacific, particularly South Korea, despite a temporary transition in China distribution [2] - The Salix segment saw an 11% growth for Xifaxan due to resilient demand and effective digital capabilities and physician engagement [2] Future Guidance and Strategic Priorities - The company achieved its 11th consecutive quarter of revenue and adjusted EBITDA growth, driven by commercial focus and operational excellence [3] - For 2026, guidance anticipates a 3% revenue increase and 4% adjusted EBITDA growth at the midpoint, with stronger growth expected in the first half [3] - Management expects China to regain its position as the top geography for Solta in 2026 following the integration of the Shibo distribution platform [3] - Strategic priorities for 2026 include leveraging AI-driven customer insights to enhance patient engagement in the Salix franchise [3] - The company plans to explore options for unlocking value, including potential monetization of its 88% equity stake in Bausch + Lomb as market valuations improve [3] - Guidance for 2027 anticipates a dip in EBITDA to approximately $2.7 billion due to new CMS rebates and loss of exclusivity for Aplenzin [3]